Article Text

Download PDFPDF
Anti-ANP32A antibodies in systemic sclerosis

Statistics from


  • Handling editor Josef S Smolen

  • Contributors All authors were involved in drafting the letter and revising it critically for intellectual content, and all authors approved the final version to be published. Study conception and design were done by LC-R and AAS. Acquisition of data was done by LC-R and AAS. RW, LC-R and AAS were involved in analysis and interpretation of data.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.